Acuren Corp
NYSE:TIC

Watchlist Manager
Acuren Corp Logo
Acuren Corp
NYSE:TIC
Watchlist
Price: 10.355 USD -7.54%
Market Cap: $2.3B

Acuren Corp
Investor Relations

Acuren Corp. engages in providing nondestructive testing, inspection, engineering and lab testing services. The company is headquartered in Tomball, Texas. The company went IPO on 2023-10-12. The firm provide these essential and often compliance-mandated (often at customer locations) services in the industrial space and are focused on the recuring maintenance needs of its customers. The firm operates in the service category referred to as Testing, Inspection and Certification (TIC). These activities include Nondestructive Testing (NDT) techniques such as radiography, ultrasonic testing, magnetic particle inspection, penetrant testing, and visual inspection. NDT activities include inspection and evaluation of industrial equipment through various technology-enabled methods to ensure asset integrity, avoid costly accidents and comply with regulatory requirements without destroying the asset or component. The company operates from approximately 119 service centers and over 22 engineering and lab facilities. The company operates in the United States and Canada, and has limited operations located in the United Kingdom.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 12, 2025
AI Summary
Q3 2025

Revenue Growth: TIC Solutions reported Q3 revenue of $473.9 million, reflecting substantial year-over-year growth due to the NV5 acquisition. Combined year-to-date revenue grew approximately 4.7%.

Guidance Reaffirmed: Management reaffirmed full-year 2025 revenue guidance of $1.530 billion to $1.565 billion and adjusted EBITDA of $240 million to $250 million, with 2026 revenue expected to grow 3–5%.

Synergy Target Raised: The cost synergy target from the NV5 acquisition was increased from $20 million to $25 million, expected to be fully realized by mid-2027.

Strong Data Center Momentum: Data center revenue more than doubled year-to-date but remains a small (~3%) part of the mix, with significant growth ambition and cross-segment expansion.

Segment Performance: Consulting Engineering saw double-digit growth, Geospatial performed well with mid-single-digit gains, while Inspection and Mitigation faced project timing and chemical sector softness.

Capital Strengthened: A $250 million equity raise in October bolstered the balance sheet, with focus on deleveraging and ongoing M&A.

Integration on Track: Integration of Acuren and NV5 is progressing, with early cross-selling and operating model alignment supporting long-term growth.

Key Financials
Revenue
$473.9 million
Adjusted EBITDA
$77.3 million
Adjusted Gross Profit
$171 million
Adjusted Gross Margin
36.1%
Inspection and Mitigation Revenue
$293 million
Inspection and Mitigation Adjusted Gross Margin
28.5% (quarter); 27.7% (year-to-date)
Consulting Engineering Revenue
$122 million (2-month stub); $189 million (full quarter pro forma)
Consulting Engineering Adjusted Gross Margin
51.4%
Geospatial Revenue
$62 million (2-month stub); $90 million (full quarter pro forma)
Geospatial Adjusted Gross Margin
48.4%
Adjusted SG&A
$93 million
Operating Cash Flow (9 months)
$45 million
Capital Expenditures (9 months)
$21 million (2.1% of revenue)
Total Liquidity (as of 9/30/25)
$282.9 million
Cash and Cash Equivalents
$164.4 million
Available Credit Facility
$118.5 million
Term Loan Debt
$1.6 billion
Equity Raise (October)
$250 million
Cost Synergy Target
$25 million
Other Earnings Calls

Management

Mr. Talman B. Pizzey
President, CEO & Director
No Bio Available
Ms. Fiona E. Sutherland
General Counsel & Corporate Secretary
No Bio Available
Ms. Kristin B. Schultes
Chief Financial Officer
No Bio Available
Anthony Gaucher
Chief Human Resources Officer
No Bio Available
Mr. Frank Noble
Executive Vice President of Operations - US
No Bio Available

Contacts

Address
TEXAS
Tomball
14434 Medical Complex Drive, #100
Contacts
+18002187450
www.acuren.com